Advances and Challenges in Prostate Cancer Diagnosis: A Comprehensive Review
Cancers · 25.06.2025 · 17 (13) · 2137
DOI: 10.3390/cancers17132137 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 25.06.2025. Verfasst von Emil Kania und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Śniadeckiego Voivodeship Hospital in Bialystok, 26 Sklodowskiej-Curie St., 15-278 Bialystok, Poland. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 153 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Bialystok, Poland.
Abstract (Originalsprache)
Prostate cancer is the most commonly diagnosed malignancy in men and continues to be a leading cause of cancer-related mortality. Accurate and timely diagnosis is essential for distinguishing clinically significant tumors from indolent lesions and for informing treatment decisions. Multiparametric magnetic resonance imaging (mpMRI) has revolutionized prostate cancer detection by enabling precise lesion localization, risk stratification, and improved biopsy targeting. Fusion biopsy, which combines mpMRI findings with real-time transrectal ultrasonography (TRUS), has emerged as a highly effective method for sampling suspicious lesions. This review provides an integrated anatomical, epidemiological, technical, and clinical overview that highlights the evolving role of fusion biopsy in contemporary prostate cancer diagnostics. We also explore emerging strategies such as penumbra-targeted sampling, discuss ongoing clinical challenges, and examine the impact of biopsy underestimation and lack of standardization. Compared to conventional systematic biopsy, mpMRI-TRUS fusion biopsy improves the detection of clinically significant prostate cancer while reducing the overdiagnosis of low-risk tumors. To our knowledge, few recent reviews have comprehensively synthesized current clinical guidelines, emerging biopsy techniques, and future directions within a single narrative. mpMRI-TRUS-guided fusion biopsy represents a major advancement in the prostate cancer diagnostic pathway, promoting precision oncology by reducing overtreatment and facilitating individualized patient care. This review aims to assist clinicians in adopting biopsy innovations that enhance diagnostic accuracy and improve patient outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Śniadeckiego Voivodeship Hospital in Bialystok, 26 Sklodowskiej-Curie St., 15-278 Bialystok, Poland.
- Department of Radiology, Śniadeckiego Voivodeship Hospital in Bialystok, 26 Sklodowskiej-Curie St., 15-278 Bialystok, Poland.
- Department of Radiology, Medical University of Bialystok, 24A Sklodowskiej-Curie St., 15-276 Bialystok, Poland.
- Department of Paediatric Radiology, Medical University of Bialystok, 17 Waszyngtona St., 15-274 Bialystok, Poland.
- Department of Integrated Medical Care, Medical University of Bialystok, 7A Sklodowskiej-Curie St., 15-096 Bialystok, Poland.
ORCID-Profile: Emil Kania, Maciej Janica, Miłosz Nesterowicz, Mateusz Cybulski, Jacek Janica
Förderung
- Medical University of Bialystok, Poland
Zitieren
APA
Kania, E., Janica, M., Nesterowicz, M., Modzelewski, W., Cybulski, M., & Janica, J. (2025). Advances and Challenges in Prostate Cancer Diagnosis: A Comprehensive Review. Cancers, 17(13), 2137. https://doi.org/10.3390/cancers17132137
Vancouver
Kania E, Janica M, Nesterowicz M, Modzelewski W, Cybulski M, Janica J. Advances and Challenges in Prostate Cancer Diagnosis: A Comprehensive Review. Cancers. 2025;17(13):2137. doi:10.3390/cancers17132137
BibTeX
@article{Kania2025,
author = {Kania, Emil and Janica, Maciej and Nesterowicz, Miłosz and Modzelewski, Wojciech and Cybulski, Mateusz and Janica, Jacek},
title = {Advances and Challenges in Prostate Cancer Diagnosis: A Comprehensive Review},
journal = {Cancers},
year = {2025},
volume = {17},
number = {13},
pages = {2137},
doi = {10.3390/cancers17132137}
}
EUVIMED